Takeda Pharmaceutical Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jul 14, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jul 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Takeda filed a 6-K on 7/14/25, confirming its Tokyo HQ and 20-F reporting.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on July 14, 2025, reporting as a foreign private issuer. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan. Takeda is registered with the SEC under file number 001-38757 and will file its annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for Takeda Pharmaceutical as a foreign private issuer, confirming its reporting status and principal office location.
Risk Assessment
Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- 001-38757 (company) — SEC File Number
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
- July 2025 (date) — Reporting Period
- July 14, 2025 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the registrant makes or is required to make public pursuant to the laws of its home country, or that is made or is required to be made public to any stock exchange on which it has securities listed, or that is distributed or is required to be distributed to its security holders.
What is Takeda Pharmaceutical's SEC file number?
Takeda Pharmaceutical's SEC file number is 001-38757.
Where are Takeda Pharmaceutical's principal executive offices located?
Takeda Pharmaceutical's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.
Which form does Takeda Pharmaceutical use for its annual reports?
Takeda Pharmaceutical files its annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
This Form 6-K was filed on July 14, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 14, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).